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ABSTRACT
Glioblastoma cells feature mammalian target of rapamycin (mTOR) up-regulation 
which relates to a variety of effects such as: lower survival, higher infiltration, high 
stemness and radio- and chemo-resistance. Recently, it was demonstrated that mTOR 
may produce a gene shift leading to altered protein expression. Therefore, in the 
present study we administered different doses of the mTOR inhibitor rapamycin to 
explore whether the transcription of specific genes are modified. By using a variety 
of methods we demonstrate that rapamycin stimulates gene transcription related to 
neuronal differentiation while inhibiting stemness related genes such as nestin. In 
these experimental conditions, cell phenotype shifts towards a pyramidal neuron-like 
shape owing long branches. Rapamycin suppressed cell migration when exposed to 
fetal bovine serum (FBS) while increasing the cell adhesion protein phospho-FAK 
(pFAK). The present study improves our awareness of basic mechanisms which relate 
mTOR activity to the biology of glioblastoma cells. These findings apply to a variety 
of effects which can be induced by mTOR regulation in the brain. In fact, the ability 
to promote neuronal differentiation might be viewed as a novel therapeutic pathway 
to approach neuronal regeneration.
INTRODUCTION
Glioblastoma multiforme (GBM, grade IV 
astrocytoma) is the most common and highly malignant 
brain tumor, which intensely proliferates, infiltrates, and 
produces relapses early, during its progression [1, 2].
Among various molecular hallmarks, GBM cells are 
characterized by up-regulation of the molecular complex 
known as mammalian target of rapamycin (mTOR). 
In particular, mTOR up-regulation is related to lower 
survival [3, 4], higher infiltration [5-7], higher amount of 
stem cells [8-13], and higher resistance to radio- [7, 14-16] 
and chemo-therapy [17].
Despite mTOR is pivotal in regulating cell 
metabolism by acting on a number of cell functions [18-
20], its activity is strongly related to the inhibition of 
the autophagy pathway. In fact, autophagy suppression 
represents another hallmark of GBM cells as demonstrated 
by using a variety of experimental approaches [21, 22].
In previous studies we demonstrated that the mTOR 
inhibitor rapamycin suppresses the growth of GBM both 
in vivo in mouse brain xenograft as well as in vitro both 
in cell lines and in patient-derived cell cultures. Previous 
studies we co-authored, evidenced by cytofluorimetry that 
these effects in GBM cells are associated with inhibition 
of cell growth and suppression of cell migration rather 
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than a frank cytotoxicity [5, 23]. In a recent manuscript 
it was demonstrated that mTOR inhibition as well as 
temozolomide may produce a phenotypic shift led by gene 
modulation and altered protein expression [24, 25]. These 
phenotypic changes were related to cell proliferation, 
colony formation and migration and can be reproduced 
by rapamycin-induced altered gene expression. Therefore, 
in the present study we administered different doses of 
the mTOR inhibitor rapamycin to explore whether a 
dose-response variation in the transcription of specific 
genes was induced concomitantly with a wide range of 
phenotypic variations which were never simultaneously 
explored so far. These variations encompass cell number, 
gross cell morphology, the amount and the length of 
newly developed cell branches, the variations in the 
expression of the stem-like protein nestin as well as 
early mitotic (βIII-tubulin and NeuroD) and late post-
mitotic (NeuN) neuronal markers and the glial fibrillary 
acidic protein (GFAP). The expression of these proteins 
was measured by using immunohistochemistry as well 
as immunoelectronmicroscopy and SDS-Page immune-
blotting. The pattern of protein expression was backed 
up by measuring transcripts by quantitative real time- 
polymerase chain reaction (qRT-PCR). These phenotypic 
changes induced by increasing doses of rapamycin 
were correlated with suppression of mTOR activity 
(dose-dependent decrease of p6S) and inhibition of cell 
migration, which was further related to the expression 
of the migration-related adhesion protein phospho-FAK 
(pFAK). All these findings occurred consistently along 
three different GBM cell lines with only slight variations 
in the dose-response curves.
RESULTS
Effects of low doses of rapamycin on the number 
of U87MG cells
In U87MG cells increasing doses of rapamycin, 
from 1 nM up to 1 µM for 24 h, were administered to 
produce increasing inhibition of mTOR. Rapamycin 
exposure decreases the number of cells, which is 
significant at the dose of 10 nM, and progresses at the 
doses of 100 nM and 1 µM (Figure 1). This reduction in 
cell number was not dependent on cell death. In fact, when 
we counted the number of trypan blue-stained cells, no 
Figure 1: Rapamycin dose-dependently reduces the number of U87MG cells. Representative pictures of non-fixed, non-
stained U87MG cells treated either with vehicle (control) A. or rapamycin (1 nM, B. 10 nM, C. 100 nM, D. 1 µM, E.) for 24 h. The graph 
reports the total number of cells counted in 1 ml by using the Bürker chamber F. Values are given as the mean±S.E.M. Comparisons 
between groups were made by using one-way ANOVA with Scheffé post-hoc test. **P ≤ 0.05 vs control and 1 nM rapamycin. ***P ≤ 0.05 
vs control and rapamycin at 1 nM and 10 nM. Scale bar = 27 µm.
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significant difference was found for any dose of rapamycin 
used compared with baseline conditions (Figure 1F). 
This is in line with what we published previously [23], 
when we demonstrated, by using cytofluorimetry that in 
U87MG and GBM patient cells, a short-time treatment 
of rapamycin arrests cell proliferation. Autophagy and 
apoptotic cell death could be observed only in a few cells 
when rapamycin was administered for longer times at very 
high doses. Similarly, when tested in other cell lines, the 
very same doses of rapamycin produced a decrease in the 
number of U251MG (Supplementary Figure 1) and A172 
cells (Supplementary Figure 2) which was significant at 1 
µM and 100 nM, respectively.
Effects of low doses of rapamycin on the U87MG 
cell morphometry
Exposure to increasing doses of rapamycin 
produced dose-dependently morphological changes. In 
fact, the typical fusiform cell body, observed in control 
Figure 2: Rapamycin dose-dependently modifies cell morphology and cell branches. Representative pictures of H&E-stained 
U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h 
B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM 
(C); 100 nM (D); 1 µM (E) of rapamycin exposure. These dose-dependent changes in the shape of the cell body are associated with a dose-
dependent increase both in the number and length of cell branching, as reported in the graphs (F. and G., respectively). Values are given as 
the mean±S.E.M. Comparisons between groups are made by using one-way ANOVA with Scheffé post-hoc test. *P ≤ 0.05 vs control. **P 
≤ 0.05 vs control and 1 nM rapamycin. Scale bar = 18 µm.
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cells (Figure 2A), disappears and rapamycin-treated cells 
develop, dose-dependently, a neuron-like pyramidal cell 
body with increased branching (Figures 2B-2E). These 
changes occur along with an increase both in number and 
length of cell branches (Figure 2). In detail, in control 
cells we counted 0.7±0.1 branches per cell, whereas in 
rapamycin-treated cells the amount of branches increases 
up to 4.2±0.2 reaching a plateau at the dose of 10 nM, 
(Figure 2F). In rapamycin-treated cells the increase in 
the number of cell branching was counted concomitantly 
with the measurement of increasing length of each branch 
(Figure 2G). In fact, while in control cells the mean length 
per branch was 4.3±0.3 µm, following 1 nM rapamycin 
the length increases to 46.8±2.3 µm. The branch lenght 
further increases dose-dependently to reach a plateau: 
61.2±2.2 µm at 10 nM, and 68.3±1.5 and 68.6±1.6 µm at 
100 nM and 1 µM of rapamycin, respectively (Figure 2G). 
Remarkably, the amount of the effects produced from each 
dose of rapamycin (above 10 nM) was underestimated 
compared with controls since we missed on purpose those 
branches measuring length above 300 µM. This was done 
to keep the measurement within a range of length allowing 
to visualize the branch reliably along its course in the same 
focal plane. Indeed following rapamycin a few branches 
surpassed the length of 300 µM, although no difference 
in their number was counted between rapamycin doses 
above 10 nM leaving intact the differences between 
groups for these high rapamycin doses. A dose-dependent 
increase in the length of cell branching was also observed 
in rapamycin-treated U251MG (Supplementary Figure 
3) and A172 cells (Supplementary Figure 4), whereas in 
neither these cell lines rapamycin was able to induce an 
increase in the number of cell branches (Supplementary 
Figures 3 and 4).
Figure 3: Rapamycin dose-dependently reduces nestin while increasing βIII-tubulin and NeuN mRNAs. Specific gene 
expression was assessed by quantitative real-time PCR analysis (means from two different experiments normalized with two different 
internal references) for nestin, βIII-tubulin and NeuN in U87MG cells in control conditions and following 4 h A. and 24 h B. of 10 nM, 100 
nM and 1 µM rapamycin. Data are expressed as the means±SEM. Comparison between groups are made by using one-way ANOVA with 
Bonferroni test. *P ≤ 0.05 vs respective control. **P ≤ 0.05 vs respective control and 10 nM rapamycin.
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Figure 4: Low doses of rapamycin dose-dependently reduce nestin in U87MG cells. Immune-fluorescence of U87MG cells 
treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H. 100 nM I.-L. 1 µM M.-P. In the first line cells were stained for the 
stem cell marker nestin. Rapamycin produces a dose-dependent decrease of nestin immune-fluorescence. In the second line cells were 
stained for the nuclear dye DAPI. In the third line the merging between nestin (green) and DAPI (blue) fluorescence is shown. In the fourth 
line, a high magnification of the squared insert of line three is shown. The graph reports the percentage of nestin-positive cells in control 
and after treatment with different doses of rapamycin. Values are given as the mean±S.E.M. Comparisons between groups are made by 
using one-way ANOVA with Scheffé post-hoc test. *P ≤ 0.05 vs control. **P ≤ 0.05 vs control and 10 nM rapamycin. Scale bars = (A-C, 
E-G, I-K, M-O) 155 µm; (D, H, L, P) 45 µm.
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Figure 5: Rapamycin dose-dependently reduces nestin immune-cytochemistry. Representative pictures of immune-
cytochemistry for nestin in control cells (A-C). Nestin immune-gold particles are localized in the nucleus (arrowheads) and cytoplasm 
(arrows), over/under the plasma membrane (thick arrows) and they are placed with autophagy-like vacuoles (*) A. Nestin immune-gold 
particles (arrow) are present on cytoplasmic filaments (thick arrow) B. and in a narrow space between two cells which appear to be 
connected by a bridge of the plasma membrane (*) C. The graph reports the rapamycin-induced dose-dependent decrease in the counts of 
nestin immune-gold particles (10 nM; 100 nM and 1 µM). Values are given as the mean±S.E.M. Comparisons between groups are made by 
using one-way ANOVA with Scheffé post-hoc test. *P ≤ 0.05 vs control. Scale bars= (A, B) = 0.19 μm; (C) = 0.22 μm.
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The stemness antigen nestin is suppressed dose-
dependently by rapamycin
Despite the transcript of nestin was not affected at 4 
h following each dose of rapamycin (Figure 3A), qRT-PCR 
carried out at 24 h following rapamycin administration 
indicates a dose-dependent decrease of the stem cell 
marker nestin (Figure 3B). As reported for morphological 
changes in the previous paragraph, we documented a 
remarkable decrease (almost 50%) in nestin which is 
already significant for the dose of 10 nM of rapamycin. 
Higher doses of rapamycin further decrease only slightly 
nestin transcript levels. The reduction of nestin mRNA 
produced by rapamycin was consistent independently 
from the transcript used as internal reference, as detailed in 
Supplementary Figure 5 (which reports the consistency of 
quantitative data for each mRNA along with two different 
ratio for the internal reference mRNA, actin or globin). 
A progressive dose-dependent decrease of nestin mRNA 
was also observed in U251MG and A172 cells at 24 h 
after rapamycin administration (Supplementary Figure 6). 
Immune-fluorescence for nestin overlaps with qRT PCR 
data showing showing a remarkable decrease already for 
the lowest dose of rapamycin. Only the highest rapamycin 
dose produced a further significant reduction in nestin 
(Figure 4 graph). In representative pictures of Figure 4 it is 
evident the intense nestin immune-fluorescence in control 
conditions, which markedly decreases dose-dependently 
under the effects of rapamycin. The loss of cell staining 
strikingly contrasts with preservation of the number of 
cells as represented in the second line by DAPI immune-
fluorescence and by merging pictures reported in the third 
line. The lowest line provides a higher magnification 
which allows to appreciate how the reduction in nestin 
is the consequence of both a decrease in the number of 
immune-positive cells and the decrease of stainable 
antigens within each cell. As a side observation, in these 
pictures one can appreciate the wide nuclear volume 
produced by the highest doses of rapamycin as evidenced 
by DAPI fluorescence which confirms the morphological 
changes reported with Haematoxylin & Eosin (H&E) 
staining of Figure 2.
Figure 6: Rapamycin dose-dependently reduces nestin assessed by immune-blotting. Representative immune-blots for nestin 
and the housekeeping protein β-actin in control and rapamycin-treated U87MG cells. The ratio between the optical densities of nestin and 
β-actin is reported in the graph. Rapamycin reduces nestin dose-dependently. Values are given as the mean±S.E.M. Comparisons between 
groups were made by using one-way ANOVA with Bonferroni test. **P ≤ 0.05 vs control and 10 nM rapamycin. ***P ≤ 0.05 vs control 
and rapamycin at 10 nM and 100 nM.
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Figure 7: Rapamycin dose-dependently increases βIII-tubulin immune-fluorescence. Immune-fluorescence of U87MG cells 
treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H. 100 nM I.-L. 1 µM M.-P. In the first line cells were stained for the 
early neuronal marker βIII-tubulin. Rapamycin increases dose-dependently immune-fluorescence. In the second line cells were stained for 
the nuclear dye DAPI. In the third line the merging between βIII-tubulin (green) and DAPI (blue) fluorescence is shown. In the fourth line a 
high magnification of the squared insert of line three is shown. The graph reports the percentage of βIII-tubulin-positive cells in control and 
after treatment with different doses of rapamycin. Values are given as the mean±S.E.M. Comparisons between groups were made by using 
one-way ANOVA with Scheffé post-hoc test. *P ≤ 0.05 vs control. **P ≤ 0.05 vs control and 10 nM rapamycin. ***P ≤ 0.05 vs control and 
rapamycin at 10 nM and 100 nM. Scale bars = (A-C, E-G, I-K, M-O) 155 µm; (D, H, L, P) 45 µm.
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Figure 8: Rapamycin increases βIII-tubulin immune-cytochemistry. In representative micrograph A. scanty immune-gold 
particles for βIII-tubulin (arrow) are shown in control cells. After rapamycin immune-gold particles increase (arrow) and they are placed 
close to cytoplasmic filaments (thick arrows) B. and within cell branches C. The graph reports the dose-dependent increase in βIII-tubulin 
immune-gold particles induced by rapamycin (10 nM; 100 nM and 1 µM). Values are given as the mean±S.E.M. Comparisons between 
groups were made by using one-way ANOVA with Scheffé post-hoc test. *P ≤ 0.05 vs control. ***P ≤ 0.05 vs control and rapamycin at 10 
nM and 100 nM. Scale bars= (A) = 0.23 μm; (B) = 0.37 μm; (C) = 0.33 μm.
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Similar findings were obtained in U251MG and 
A172 cells after increasing doses of rapamycin, as shown 
in Supplementary Figures 7 and 8, respectively.
The subcellular placement of nestin can be 
appreciated following representative immune-electron 
microscopy of Figures 5A-5C, where nestin-bound 
immune-gold particles are placed both in the nucleus 
and cytoplasm, where they are more abundant within 
autophagy-like vacuoles and over the cytoplasmic 
filaments lining close to plasma membrane. The amount 
of nestin particles counted stoichiometrically through 
immune-gold particles are reduced dose-dependently 
already for the dose of 10 nM. Similar results were 
obtained when nestin immune-gold particles were 
analyzed in U251MG and A172 cells, as shown in 
representative pictures and graphs of Supplementary 
Figures 9 and 10, respectively.
The semi-quantitative measurement based on optical 
density of the ratio of immune-positive bands of nestin vs 
β-actin in U87MG cells (Figure 6) reproduces rapamycin-
induced suppression established by other methods, 
although slight differences are noticeable for increasing 
rapamycin doses. These are likely to rely on the lower 
detection sensitivity and specificity of immune-blotting 
compared with quantitative methods reported above.
Rapamycin dose-dependently increases βIII-
tubulin
As reported in Figure 3, rapamycin produces an 
increase in the mRNA for βIII-tubulin at 24 h but not 
at 4 h of exposure. This increase in βIII-tubulin occurs 
harmonically for various doses of rapamycin. Thus, 
the highest rapamycin dose still produces a significant 
increase compared with other doses of rapamycin 
(Figure 3B). A similar dose-dependent increase in the 
mRNA for βIII-tubulin at 24 h of rapamycin exposure 
was obtained in both U251MG and A172 cell lines, as 
reported in Supplementary Figure 6. Again, data from 
immune-fluorescence remarkably overlap with qRT-PCR 
data showing that the early neuronal marker βIII-tubulin 
steadily increases along a logarithmic scale of rapamycin 
doses, each dose being significantly more effective than 
the lower one. This is analytically evidenced in the graph 
of Figure 7 and it is representatively reported in pictures of 
Figures 7A-7P, where the increase in βIII-tubulin recruits 
the total amount of the cells, with each cell becoming 
more and more intensely stained along the dose-response 
curve (Figures 7D, 7H, 7L, 7P). The constant progression 
occurring dose-dependently for βIII-tubulin immune-
fluorescence was replicated in both U251MG and A172 
cells (Supplementary Figures 11 and 12, respectively). 
When βIII-tubulin immune-gold was carried out, the 
increase was confirmed showing detailed and fine 
distribution of this early neuronal marker. It is worth being 
noticed that this marker was already present, albeit at very 
low concentrations, in control cells (representative Figure 
8A). This unexpected occurrence confirms what already 
reported in the literature [26, 27], thus toning down the 
absolute significance of this antigen as a fully reliable 
neuronal marker. In fact, βIII-tubulin may also occur 
quite ubiquitously in low amount owing a non specific 
significance. This is why we matched the βIII-tubulin 
data with NeuroD and NeuN since the simple βIII-tubulin 
immune-staining was already reported by Zhuang et al. 
[16]. Nonetheless, here rapamycin produces a strong and 
specific dose-dependent increase of βIII-tubulin staining, 
which augments significantly even for the highest dose 
of rapamycin (Figures 8B and 8C and graph of Figure 
8). An increase in βIII-tubulin immune-gold was also 
observed in rapamycin-treated U251MG and A172 cells 
(Supplementary Figures 13 and 14, respectively), although 
in U251MG cell line this effect was significant only at the 
highest dose of rapamycin (1 µM). A similar trend was 
measured by semi-quantitative optical density of western 
blotting for βIII-tubulin in U87MG cells (Figure 9). It is 
worth to be mentioned that, among the various antigens 
we measured in these experiments, the neuronal antigens 
βIII-tubulin and NeuN do not reach a plateau with the 
highest dose of rapamycin. This is in striking contrast with 
the effects produced for the stemness antigen nestin which 
are almost complete at low doses of rapamycin. These 
data which differ slightly between cell lines, indicate 
that neuronal differentiation and the loss of stemness 
follow two separate dose-response curve, thus suggesting 
independent pathways, both under the regulation of 
mTOR, to be responsible for these phenomena. When the 
fine morphology of βIII-tubulin is analyzed, the protein 
was found in strong association with cytosolic filaments. 
As mentioned, to confirm the effects of rapamycin on 
the induction of early neuronal markers, we also counted 
the number of NeuroD positive cells under the effects of 
various doses of rapamycin, in both U87MG and A172 
cell lines, as reported in Supplementary Figures 15 and 16, 
respectively. This marker is quite similar to βIII-tubulin 
concerning neuronal maturation [28-30]. The increase 
in NeuroD produced by rapamycin confirms what we 
measured for βIII-tubulin and lend substance to βIII-
tubulin data obtained by Zhuang et al. [16].
Rapamycin dose-dependently increases NeuN
The induction of early neuronal markers staining 
neuronal precursors during a mitotic stage does no 
guarantee for the occurrence of a frank neurogenesis. Thus, 
to strengthen the early findings of Zhuang et al. [16] and 
our extended analysis of early neuronal markers presented 
so far, the post-mitotic antigen NeuN was extensively 
analyzed. In qRT-PCR experiments, the mRNA for the 
late (post-mitotic) neuronal marker NeuN [31-33] was 
quantified as steadily increasing dose-dependently under 
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rapamycin exposure in U87MG cells (Figure 3) as well as 
in both U251MG and A172 cells at 24 h (Supplementary 
Figure 6). Remarkably, the transcript for NeuN possesses 
the highest sensitivity to mTOR inhibition among all other 
markers. In fact, the mRNA for this antigen was highly 
increased at 24 h and it was the only one to be modified at 
4 h in U87MG cells, when the mRNA was unexpectedly 
decreased for the highest rapamycin doses. Immune-
fluorescence for NeuN is shown in representative pictures 
from control and rapamycin-treated U87MG (Figure 
10) and A172 cells (Supplementary Figure 17). Such an 
increase progresses up to the highest dose of rapamycin 
(Figure 10P and Supplementary Figure 17P), as counted 
in both graphs of Figure 10 and Supplementary Figure 17, 
which report a further net increase even for the highest 
dose of rapamycin. This trend was preserved in semi-
quantitative counts reported for western blotting carried 
out in U87MG (Figure 11).
Western blotting for each specific antigen confirms 
the trend obtained with other methods. Nonetheless, when 
compared with quantitative procedures such as immune-
electron microscopy, counts at immune-histochemistry, 
and qRT-PCR, data from western blotting are in line 
but with slight differences. This is not surprising due to 
variability of regression curves obtained by measuring 
optical density versus protein amount for each specific 
antigen. This is both antigen-dependent and it is inherently 
due to a “semi-quantitative procedure” which does not 
allow to draw a linear ratio (or any constant mathematical 
function) to correlate increasing optical density and 
increasing protein amount. In other words, protein 
measurement by western blotting is expressed by arbitrary 
units produced by optical density, which varies in the 
shape of regression curves for standard doses depending 
on each specific antigen/antibody complex and changes 
at various range of doses. These limits are inherent to 
the methods and need to take cautiously differences 
between groups which are measured for optical density 
(consistent increase or decrease rather than emphasizing 
slight variations). Strikingly, the data obtained through 
quantitative approaches we provided here are quite 
overlapping and they best define the slight effects, which, 
in any case, are similar to western blotting.
Figure 9: Rapamycin dose-dependently increases βIII-tubulin assessed by immune-blotting. Representative immune-
blotting showing βIII-tubulin and the housekeeping protein β-actin in control and rapamycin-treated U87MG cells. The graph report the 
βIII-tubulin/β-actin ratios between optical densities showing that rapamycin increases dose-dependently βIII-tubulin. Values are given as 
the mean±S.E.M. Comparisons between groups were made by using one-way ANOVA with Bonferroni test. *P ≤ 0.05 vs control.
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Figure 10: Rapamycin dose-dependently increases NeuN immune-fluorescence. Immune-fluorescence of U87MG cells 
treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 µM M.-P. In the first line cells were stained for 
the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging 
between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is 
shown. The graph reports the dose-dependent rapamycin-induced increase in NeuN-positive cells. Values are given as the mean±S.E.M. 
Comparisons between groups were made by using one-way ANOVA with Scheffé post-hoc test. *P ≤ 0.05 vs control. **P ≤ 0.05 vs control 
and 10 nM rapamycin. Scale bars = (A-C, E-G, I-K, M-O) 155 µm; (D, H, L, P) 45 µm.
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Rapamycin does not modify GFAP
Increasing doses of rapamycin never alter the 
amount of GFAP positive cells which were barely 
detectable. Similarly, the GFAP signal which was clearly 
detected at western blotting was not modified by any 
dose of rapamycin (Figure 12 and Figure 13). These 
data indicate the lack of effects of rapamycin towards 
phenotype of glial activation, which is in line with 
previous data showing that mTOR inhibition does not 
induce glial differentiation [34-36].
Effects of rapamycin on FBS-induced cell 
migration and pFAK expression
In seeking to provide a functional link between 
consistent formal evidence about rapamycin-induced cell 
differentiation and functional cell properties, we analyzed 
whether, in the same experimental conditions, fetal 
bovine serum (FBS)-induced migration of U87MG cells 
was similarly affected by different doses of rapamycin. 
In Figure 14 representative micrographs report a dose-
dependent rapamycin-induced inhibition of FBS-induced 
migration which was calculated in the graph at 24 h and 
72h of treatment. This was observed only for those cells 
migrating towards FBS, whereas it was not detectable 
in cells migrating towards a medium without FBS (with 
the exception of the highest doses). This suggests that 
rapamycin has specific effects on cell chemotaxis while 
is not specific for cell chemokinesis. Data related to 
cell migration obtained in U251MG and A172 cells at 
24 h and 72 h after rapamycin exposure were reported 
in Supplementary Figures 18 and 19, respectively. 
Remarkably, in these additional cell lines a reduced 
motility was observed even within a medium without FBS 
for the lower doses of rapamycin. Since chemotaxis relies 
on the expression of the adhesion molecule pFAK, we 
carried out experiments on U87MG treated with different 
doses of rapamycin using pFAK immune-fluorescence. 
Figure 11: Rapamycin dose-dependently increases NeuN assessed by immune-blotting. Representative immune-blots for the 
late neuronal marker NeuN and the housekeeping protein β-actin. The ratio between the optical densities of NeuN and β-actin is reported 
in the graph. Rapamycin increase NeuN dose-dependently. Values are given as the mean±S.E.M. Comparisons between groups were made 
by using one-way ANOVA with Bonferroni test. *P ≤ 0.05 vs control. **P ≤ 0.05 vs control and 10 nM rapamycin.
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Figure 12: Rapamycin does not modify GFAP immune-fluorescence. Immune-fluorescence of U87MG cells treated with vehicle 
A.-D. and rapamycin at the dose of 10 nM E.-H. 100 nM I.-L.; 1 µM M.-P. In the first line cells were stained for the glial marker GFAP. In 
the second line cells were stained for the nuclear dye DAPI. In the third line the merging between GFAP (red) and DAPI (blue) fluorescence 
is shown. In the fourth line a high magnification of the squared insert of line three shows that GFAP-positivity is not modified following 
treatment with rapamycin compared with baseline conditions. Counts reported in the graph confirm the lack of any effect. Values are given 
as the mean±S.E.M. Comparisons between groups were made by using one-way ANOVA with Scheffé post-hoc test. Scale bars = (A-C, 
E-G, I-K, M-O) 155 µm; (D, H, L, P) 45 µm.
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As shown in representative pictures of Supplementary 
Figure 20, in the presence of FBS the chemotaxis-related 
antigen was highly expressed, while such an expression 
was suppressed dose-dependently by rapamycin 
administration. This correlates with the suppression of cell 
migration measured in the graph of Figure 14. In detail, the 
highest doses of rapamycin produces an amount of pFAK 
expression comparable with control (non FBS exposed) 
cells (Supplementary Figure 20). Similar results were also 
obtained in U251MG cells (Supplementary Figure 21). In 
these sets of experiments, the lab carried out pilot studies 
to assess cell viability through the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 
each cell line, as reported in Supplementary Figures 22 
and 23. This was carried out to test the cell culture during 
migration experiments. In these experimental conditions 
at 24 h, and mostly at 72 h, a few cell death was measured 
according to MTT, which confirms a neglectable amount 
of cell death only for the highest rapamycin doses we 
previously measured using this assay. This is demonstrated 
to depend almost entirely on autophagy while apoptosis is 
neglectable [23].
Rapamycin dose-dependently suppresses pS6
In order to validate the occurrence of mTOR 
inhibition under the effects of increasing doses of 
rapamycin, we performed an immune-blot analysis for 
the ribosomal protein p6S, commonly used as index of 
mTOR activity since it is located downstream to mTOR 
activation. Consistently with most of the dose-response 
curve produced by different methods reported in the 
previous paragraph, we found that rapamycin suppresses 
p6S protein expression already at the dose of 10 nM in 
each cell line (Supplementary Figures 24-26). Remarkably, 
in A172 cells we measured the most severe suppression 
which is consistent with the highest sensitivity of A172 
cells to most of the effects induced by rapamycin. This 
strongly suggests that all these effects indeed depend on 
mTOR inhibition (Supplementary Figure 26).
DISCUSSION
In the present study we report several lines of 
evidence, based on a number of different experimental 
Figure 13: Rapamycin does not modify GFAP as assessed by immune-blotting. Representative immune-blots of GFAP and 
the housekeeping protein β-actin in control and rapamycin-treated U87MG. The ratio between the optical densities of GFAP and β-actin is 
reported in the graph and it confirms that GFAP expression is not modified by rapamycin. Values are given as the mean±S.E.M. Comparisons 
between groups were made by using one-way ANOVA with Bonferroni test.
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procedures carried out in different GBM cell lines, 
which demonstrate the molecular effects produced by the 
powerful mTOR inhibitor, rapamycin. Rapamycin strongly 
modulates the expression of specific mRNA by stimulating 
the transcription of those genes related to neuronal 
differentiation while inhibiting the production of mRNA 
coding for the stemness antigen nestin. At the same time 
rapamycin produces a variety of phenotypic alterations, 
each one in a dose-dependent manner starting from very 
low doses of the compound. In fact, most of these effects 
were produced significantly by a dose of 10 nM which 
is normally produced by administering therapeutic doses 
of such mTOR inhibitor. Remarkably, when we analyzed 
the mTOR inhibition expressed by suppression of the 
downstream product of mTOR Complex 1 (mTORC1) 
activity p6S, the dose of 10 nM was fully effective. 
These results extend the effects of rapamycin on cell 
differentiation described by Zhuang et al. [16] who use 
only one very high dose rapamycin (200 nM) way higher 
compared with the therapeutic range. In fact, this is a 
very important point. According to the Stenton review, 
the therapeutic range recommended for rapamycin to 
produce its clinical effects is 12-20 mg/L [37]. When 
considering the molecular weight of rapamycin, 914.172, 
this corresponds to a therapeutic range expressed in moles 
between 13.13 and 21.88 nM. Remarkably, in the present 
study some effects we obtained following rapamycin in 
U87MG cell line reached a plateau already at the dose of 
10 nM, which corresponds to a dose slightly below the 
therapeutic range (13-21 nM). When tested in A172 cell 
line the effects of rapamycin occurred even with lower 
doses, whereas when tested in another Uppsala derived 
cell line (U251MG) the effects produced by 10 nM were 
less pronounced but still highly significant. Thus, we 
provided evidence for a number of effects induced by 
rapamycin within its therapeutic range or even at slightly 
subthreshold doses.
The morphological evidence we provide here for 
the dose-dependent phenotypic shift represents the first 
demonstration that rapamycin, at a dosing plateau of 
10 nM modifies GBM cell morphology. This is evident 
in U87MG cells, switching towards a neuronal like 
shape with a number of long branches arising from a 
pyramidal cell body gifted with a wide nucleus. Thus, 
phenotypic changes encompass rough variations in cell 
and nuclear size, cell shape and the amount and length of 
cell branching which occur when the cell line develops 
a neuron-like morphology. Changes in the shape of the 
cell body although occurring in other GBM cell lines were 
less pronounced when considering the number of cell 
branching. These neuron-like morphological alterations 
were paralleled by a dose-response loss of stemness as 
shown by rapamycin-induced suppression of stemness-
related antigen nestin, which was quantified both as 
mRNA and protein detected as nestin immune-fluorescent 
and more carefully counted by stoichiometric quantitative 
assessment of nestin immune-gold electron microscopy. 
This was confirmed by semi-quantitative SDS-Page 
immune-blotting. Each experimental procedure provided 
similar results with the highest degree of coherency 
between quantitative methods (such as qRT-PCR and cell 
counts) compared with slight, non critical discrepancies 
detected by optical estimation of protein levels at western 
blots. Again, in most experimental setting the dose of 10 
nM rapamycin was enough to produce the maximal nestin 
suppression. At immune-gold, only when rapamycin rose 
up to 1 µM we observed a further slight suppression of 
nestin. This second peak of effects is likely to escape from 
the canonical mTOR regulation. In fact, in A172 cells 
where the effects of rapamycin were mostly correlated to 
mTOR inhibition, the suppression of nestin immune-gold 
observed for 10 nM was identical to that obtained at 100 
nM and 1 µM of rapamycin.
There is no doubt that most of the effects produced 
by rapamycin as an mTOR inhibitor in GBM cells are 
grounded on reverting a massive autophagy inhibition 
[21]. However, recent evidence demonstrates that 
other mechanisms, such as the amount of prion protein, 
may strongly affect the phenotype of GBM cells [38]. 
Interestingly, rapamycin is able to modulate prion protein 
metabolism [39], which provides an alternative pathway 
for rapamycin induced phenotypic shift of GBM cells.
This high sensitivity to phenotypic changes 
generated by rapamycin was paralleled by the expression 
of the cell adhesion antigen pFAK. This suggests similar 
biochemical cascades regulating both antigens which 
suggests a connection between differentiation and cell 
migration. Some phenotypic changes occur with a 
wider dose-response curve. Both βIII-tubulin as well as 
NeuroD can be considered as early neuronal markers 
according to current literature. The significance of 
these markers is quite similar for neuronal maturation 
being typical of ongoing neurogenesis still at mitotic 
stages, being NeuroD more restricted to some neuronal 
populations than βIII-tubulin [28-30]. Both markers, 
despite increasing robustly following the lowest dose of 
rapamycin, continued to increase significantly up to higher 
doses of the mTOR inhibitor. The neuronal antigen NeuN, 
which is considered as a late neuronal marker, specifically 
labelling post-mitotic neurons [31-33], possesses a similar 
progressive increase. The increase in NeuN is even more 
pronounced compared with early neuronal markers for 
the highest doses of rapamycin and it does not provide 
a clear evidence for the occurrence of a plateau even for 
the highest dose of rapamycin (1 µM) we used in the 
present study, which exceeds the sole dose of 200 nM 
which was used by Zhuang et al. [16]. Altogether our 
data suggest that the loss of stemness and the different 
steps in neuronal maturation are all regulated by mTOR. 
However, marked difference exist in the steepness between 
the dose-response curves of these phenomena, which 
suggests additional biochemical cascades to contribute 
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Figure 14: Rapamycin dose-dependently suppresses FBS-induced cell migration. Representative images of migrated cells 
towards a medium without or with FBS for 3h. Graphs report the migration index of U87MG cells treated for 24 h or 72 h with different 
doses of rapamycin towards a medium without or with FBS for 3h. Data are expressed as percentage of migrated cells in comparison with 
control in the absence of FBS (sum of data obtained at 24 h and 72 h, taken as 100%). Data are the mean±S.E.M. Comparisons between 
groups were made by using one-way ANOVA. *P ≤ 0.05 vs respective control. **P ≤ 0.05 vs respective control and 10 nM rapamycin. ***P 
≤ 0.05 vs respective control and rapamycin at 10 nM and 100 nM.
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differently in each effect. Altogether these data produced 
by therapeutic doses of rapamycin on GBM cells shown 
here provide a useful insight to plan combined therapy 
for the treatment of GBM by using rapamycin or other 
rapalogs, which are currently ongoing, mostly based on 
empiricism. The effects of mTOR regulation do not seem 
to involve the expression of GFAP, which confirms what 
previously reported. It should be taken into account that, in 
mature neuronal circuitries the inhibition of mTOR seems 
to produce a suppressing effect on GFAP [34-36]. In this 
biological matrix we could not confirm an inhibitory 
action of mTOR inhibition on GFAP expression. It is 
likely that there is no regulation of this gene in this cell 
type (as confirmed by the absence of mRNA alterations). 
Thus, although it might surprise that rapamycin (known as 
a suppressor of glia proliferation) does not modify GFAP 
levels, it is likely that the occurrence of small amount 
of GFAP in control cells is not the result of a canonical 
regulation of gene expression but it rather occurs due to 
the aberrancy of these cells.
The present study provides strong consistency in 
experimental evidence which encompasses a variety 
of methods used to assess various effects produced by 
rapamycin. In fact, all quantitative measurements were 
remarkably similar with slight variations when expressing 
data in arbitrary units. In fact, optical density used for 
quantify western blotting carries the intrinsic bias of non-
linear distribution of optical density related to different 
protein amount. This is witnessed by the lack of a specific 
mathematical equation for the regression curves drawn for 
protein amount and optical density along a dose-response 
curve. Anyhow, despite these slight discrepancies, the 
statistical significance was consistent with data produced 
by quantitative approaches.
Such an extensive experimental collection of 
phenotypic changes was mandatory in order to move 
up to in vivo system to validate the outcomes of each 
specific finding. Remarkably, we replicated all the results 
in different GBM cell lines. At this point one might 
consider which experimental finding deserves at most to 
be translated in vivo. The experiment we feel the most 
important to be carried out in vivo consists in measuring 
in experimental tumors the neuronal differentiation under 
the effects of rapamycin. Indeed, we just published on line 
preliminary evidence showing that rapamycin reduces 
tumor growth and may revert tumor volume by promoting 
the integration of a glioblastoma xenograft into normal 
nervous tissue [40]. This specific issue deserves further in 
depth investigation.
All phenotypic changes we report in the present 
manuscript are expected to lead to significant outcomes 
when challenged in a model of tumor infiltration. For 
instance, chemotaxis which is specifically inhibited by 
very low doses of rapamycin along with inhibition in 
the expression of the cell adhesion molecule pFAK is 
supposed to alter tumor infiltration.
A number of studies demonstrate that mTOR 
inhibition increases radio- and chemo-sensitivity [16, 17, 
41, 42] of GBM cells. For instance, Zhuang et al. [16] 
demonstrated that rapamycin may reduce the resistance 
to radiotherapy through an mTOR-dependent mechanism, 
which involves up-regulation of the autophagy pathway, 
which in turn would be responsible for the expression of 
markers for neuronal differentiation.
A number of trials are in progress to evaluate 
the effects of rapamycin analogs (rapalogs) and other 
phosphoinositide-3-kinase (PI3K)/mTOR pathway 
inhibitors as combined therapy to improve the outcome 
of chemo- and radio-therapy [11, 36, 43-45]. In fact, 
when considering all the properties of stem-like GBM-
initiating cells such as cell proliferation, expression of 
stemness antigens as well as loss of cell aggregation and 
increased cell migration, all of them are affected by mTOR 
inhibition [5, 6, 9, 16, 23, 24].
However, the effects of these drugs may be lost due 
to development of resistance against mTOR inhibitors 
which depends on the overexpression of cyclin [46-48]. 
In this case it is demonstrated that sensitivity to mTOR 
inhibitors can be reproduced by administering inhibitors 
of internal ribosome entry site (IRES)-dependent which 
impede cyclin D1 and c-MYC translation [47, 49]. The 
significance of the present study is directly related to 
get an increased awareness of basic mechanisms which 
relate mTOR activity and the biology of GBM cells. 
Nonetheless, the findings we obtained here possess an 
inherent significance which applies to a variety of cells, 
mainly neurons under the effects of mTOR regulation. In 
fact, the ability to promote neuronal differentiation might 
be viewed as a novel therapeutic pathway to approach 
neuronal regeneration. This is suggested by the different 
steps promoted by rapamycin which passes through 
stemness up to early and late post mitotic neurogenesis. 
In this way our data may be regarded also as a novel path 
to rejuvenate the brain which might be useful in aging 
disorders.
Additional mechanisms for mTOR modulation on 
neuronal regeneration
Hyperactivation of the mTOR pathway is considered 
a common feature in several tumors and represents 
the major molecular alteration in glioblastoma cells. 
However, recent findings indicate that cell growth and 
proliferation induced by mTOR might be linked to 
neuronal regeneration.
In particular, mTOR regulates axonal regeneration 
of retinal ganglion cells following optic nerve crush [50, 
51] and enhances regeneration of the corticospinal tract 
[52-55]. Some of these effects are obtained by deleting 
the phosphatase and tensin homolog PTEN, the tumor 
suppressor gene which acts upstream to mTOR in the 
mTOR pathway.
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In fact inhibition of mTOR is critical for neuronal 
differentiation.
In a transgenic model of tuberous sclerosis, 
characterized by hyperactivation of mTORC1, early 
application of rapamycin during neuroectodermal 
differentiation is able to correct aberrant neuronal 
differentiation [56]. Similarly, in a mouse model of 
Angelman syndrome, characterized by high levels of 
mTORC1 activity, rapamycin normalizes the synaptic 
signaling, regulates synaptic-related cytoskeletal elements 
and improves dendritic spine morphology of Purkinje 
cells, and improves motor performance [57].
MATERIALS AND METHODS
Cell cultures
The glioblastoma cell lines U87MG were obtained 
from Cell Bank (IRCC San Martino-IST, Genova). The 
cells were grown in the growth medium DMEM (Sigma 
Aldrich, Milan, Italy) supplemented with 10% Fetal 
bovine serum (FBS), 1% of MEM Non-Essential Amino-
Acid (MEM-NEAA), penicillin (50 IU/mL) and 100 μg 
streptomycin (Sigma). Cells were maintained at 37 °C 
in a humidified atmosphere containing 5% CO2 and the 
medium was renewed 2 times per week.
The glioblastoma cell lines U251MG were 
obtained from the European Collection of Authenticated 
Cell Cultures (ECACC) and maintained in EMEM, 
2mM L-Glutamine, 1% of MEM-NEAA, 1mM Sodium 
Pyruvate (NaP), 10% FBS, 100 IU/ml penicillin and 
100 mg streptomycin, at 37 °C, 5% of CO2 and 95% of 
humidity.
The glioblastoma cell lines A172 were obtained 
from the European Collection of Authenticated Cell 
Cultures (ECACC) and from Cell Bank (IRCC San 
Martino-IST, Genova) and maintained in Modified Eagle’s 
Medium (Euroclone, Milan, Italy) supplemented with 10% 
FBS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 mg 
streptomycin, at 37 °C, 5% of CO2 and 95% of humidity.
For cell count and immune-fluorescence experiments 
5x104 U87MG, U251MG and A172 cells were seeded on 
cover slips which were put down within 24-well plates in 
a final volume of 1 ml/well.
For electron microscopy, qRT-PCR and western 
blots assay, 1x106 cells from each cell line were seeded in 
6-well plates in a final volume of 2 ml/well.
Rapamycin treatments
Twenty-four h after seeding, cells were treated 
with increasing doses of rapamycin (namely 1 nM, 10 
nM, 100 nM and 1 µM) for 24 h. Dilutions of rapamycin 
were obtained by a stock solution (1 mM of rapamycin 
dissolved in culture medium containing 10% dimethyl 
sulfoxide, DMSO). Control cells were maintained in 
culture medium containing 0.01% DMSO.
Light microscopy and immune-cytochemistry
At the end of the treatments, culture medium was 
washed out. For each treatment, some cells were left in the 
same well plate, rinsed in PBS and rapidly observed under 
light microscope without staining, in order to document 
the status of unfixed cultures.
The remaining cells were fixed with 4% 
paraformaldehyde in PBS for 15 min and then stained with 
H&E or immune-fluorescence.
Haematoxylin & Eosin. After fixation cells were 
plunged in the Haematoxylin solution (Sigma) for 20 min, 
washed in running water, and then immersed in the Eosin 
solution (Sigma) for a few minutes. Finally, cells were 
dehydrated in increasing alcohol solutions, clarified in 
xylene and covered with DPX mounting medium (Sigma).
Immune-fluorescence for stem-like and 
differentiation antigens. The following primary antibodies 
(Ab-I) were used: rabbit polyclonal anti-nestin Ab-I 
(Abcam, Cambridge, UK), for undifferentiated, stem-like 
cells [58]; mouse monoclonal anti-glial fibrillary acidic 
protein (GFAP) Ab-I (Sigma), as a marker of glial cells; 
mouse monoclonal anti-βIII-tubulin Ab-I (Millipore, 
Billerica, MA, USA) and anti-NeuroD Ab-I (Millipore) as 
early (immature) neuronal markers (Bédard and Parent, 
2004); mouse monoclonal anti-NeuN Ab-I (Millipore) as 
late neuronal marker, which specifically label post-mitotic 
neurons [31-33]. Cells were first permeabilized by Triton 
X 0.1% for 15 min in PBS and then incubated in a blocking 
solution containing 10% normal goat serum (NGS) in PBS 
for 1 h at room temperature (RT). Cells were successively 
incubated with the Ab-I solution overnight at 4°C. The 
different Ab-I solutions were prepared in PBS containing 
2% NGS. The Ab-I were diluted as it follows: anti-nestin 
Ab-I (1:200), anti-GFAP Ab-I (1:400), anti-βIII-tubulin 
Ab-I (1:200), anti-NeuN Ab-I (1:50), and anti-NeuroD 
(1:100). After washing out with PBS, the reaction with the 
Ab-I were revealed by using the anti-mouse or anti-rabbit 
fluorescent secondary antibody Alexa Fluor 488 (1:200, 
Life Technologies, Carlsbad, CA, USA) and the anti-
mouse fluorescent secondary antibody Alexa Fluor 546 
(1:200, Life Technologies) for 1 h and 30 min. To visualize 
the cell nuclei, cells were finally incubated for 5 min with 
the nuclear dye DAPI (Sigma) diluted 1:1000 in distillated 
water. All these reactions were carried out within the well 
plate. After washing in PBS, slices were gently pulled 
out and transferred on a coverslip and mounted with the 
mounting medium Fluoroshield (Sigma).
Slices were observed using the Nikon Eclipse 80i 
light microscope equipped with a fluorescent lamp and a 
digital camera connected to the NIS Elements software for 
image analysis (Nikon, Tokyo, Japan).
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DAPI- and nestin-stained pictures were acquired 
independently and then they were merged using GIMP 
(GNU Image Manipulation Program) or NIS Elements 
software (Nikon). Final image panels were prepared using 
Photoshop.
Immune-fluorescence for the adhaesion protein 
phospho-FAK (pFAK). Cells (5x104) were plated 
on coverslips and treated with different rapamycin 
concentration in presence of 10% FBS; after 24 h cells 
were washed in PBS, fixed in 4% PFA, permeabilized 
(Triton X-100 0.1%) and blocked (1% BSA) for 1 h at RT, 
and incubated overnight at 4 °C with pFAK (Tyr397, Santa 
Cruz Biotechnology, USA) 1:500. Cells were stained 
with the fluorophore-conjugated secondary antibody 
and Hoechst for nuclei visualization and analyzed using 
fluorescence microscopy. pFAK levels were semi-
quantitatively analyzed measuring the mean fluorescence 
intensity (MFI) of each signal with a 60x magnification.
Cell counts and morphometry at light microscopy
In order to evaluate cell number, 5x103 cells were 
seeded and treated with increasing doses of rapamycin. 
At the end of the treatments, 25 μl of cell suspension were 
added to 37.5 μl PBS containing 1% of trypan blue (62.5 
μl). Cells were incubated for 5 min at room temperature, 
and 10 μl of this solution were used to perform cell count 
using a Bürker glass chamber. Values were expressed as 
number of cells/ml.
The number and length of cell branching was 
measured in H&E-stained cells and they were related to a 
total of 50 cells/group at 40 x magnification for each cell 
line. The length of cell branching was measured using the 
free software IMAGEJ.
Counts of immune-fluorescent cells were carried 
out at light microscopy at 20 x magnification. Values were 
presented as the mean percentage of immune-positive cells 
which were counted within 5 distinct microscopic fields, 
where cell distribution appeared without overlapping, 
allowing to distinctly visualize all cells. This allowed us 
to count over 500 cells for each experimental group.
Measures were carried out by two observers, 
unaware of the treatments. All data were obtained in 
triplicate.
Transmission Electron Microscopy
U87MG cells were centrifuged at 1,000 g for 5 min. 
After removal of the supernatant, pellet was thoroughly 
rinsed in PBS. Fixation was carried out with a solution 
containing 2.0% paraformaldehyde/0.1% glutaraldehyde 
in 0.1M PBS (pH 7.4) for 90 min at 4°C. This fixing 
solution allows a minimal cover of antigen epitopes 
preserving the morphology of the tissue [59]. Specimens 
were post-fixed in 1% OsO4 for 1 h at 4°C; they were 
dehydrated in ethanol and embedded in Epoxy-resin. 
For ultrastructural morphometry, sections were 
examined directly at transmission electron microscopy 
(TEM) at a magnification of 8,000x. Each grid contained 
non-serial sections to count at least ten cells.
Several grids were observed in order to obtain a total 
number of at least 50 cells for each experimental group.
Post-embedding procedure
Specimens were post-fixed in 1% OsO4 for 1h at 4°C 
and then they were dehydrated in ethanol and embedded in 
epoxy resin. Ultrathin sections were cut at ultramicrotome. 
Similarly to fixing, post-fixing and embedding procedures 
were validated on pilot studies and they were reported by 
current literature as optimal conditions for immune-gold-
based ultrastructural morphometry. The method employed 
here is a “non-classical” method, which combines 
aldehyde and mild OsO4 as first and second fixing steps 
allows minimal epitope covering while preserving cell 
architecture and providing an optimal “contrast effect” of 
various cell compartments. This method allows preserving 
sub-cellular structures with acceptable epitope integrity 
[60, 61].
Osmium enhances the contrast of various cytosolic 
compartments by delineating phospholipid membranes, 
and it prevents the formation of membranous artifacts, 
which may mimic autophagy vacuoles [62].
Post-fixed samples were then embedded using 
epoxy resin, since it is well-established and commonly 
used as embedding media for TEM, allowing an optimal 
ultrastructural resolution.
The post-embedding was carried out collecting 
ultrathin sections on nickel grids and incubating them in 
aqueous saturated sodium metaperiodate (NaIO4) at room 
temperature. NaIO4 is an oxidizing agent, which attacks 
the hydrophobic alkane side-chains of epoxy resin making 
the sections more hydrophilic and allowing a closer 
contact between immune-gold-conjugated antibodies and 
the antigens exposed on the surface of each section [60]. 
This step abets the detection of specific immune-gold 
placement within a context of subcellular integrity, which 
allows counting molecules within well-delineated specific 
cell compartments.
Immune-cytochemistry at electron microscopy
Grids were incubated with cold PBS containing 
10% goat serum and 0.2% saponin to block non-specific 
antigenic sites for 20 min at room temperature.
Following a blocking step, samples were incubated 
with Ab-I: anti-βIII-tubulin (Millipore, diluited 1:50); anti-
nestin (Abcam, diluited 1:50). Incubations were carried 
out in ice cold PBS containing 1% goat serum and 0.2% 
saponin in a humidified chamber overnight at 4°C. 
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Ultrathin sections were incubated with gold-
conjugated secondary antibodies (10 nm and 20 nm gold 
particles, Sigma) diluted 1:20 in PBS containing 1% goat 
serum and 0.2% saponin for 1 hour, at room temperature.
After rinsing in PBS, grids were incubated with 1% 
glutaraldehyde for 3 min, they were washed in distilled 
water (to remove trace of salts and preventing precipitation 
of uranyl acetate), and they contrasted with uranyl acetate 
(saturated solution in distilled water) and lead citrate to 
be finally observed by using a Jeol JEM SX 100 electron 
microscope (Jeol). Control sections were obtained by 
omitting the Ab-I and by incubating with the secondary 
antibody only.
Count of immune-gold particles
Pellets from cell lines allow an appropriate condition 
for quantitative morphometry since cells are randomly 
oriented on ultrathin sections owing a similar chance to be 
selected. In fact, counts obtained from different cell pellets 
possess a very small standard error [59, 63].
Finally, specimens consist of pellet blocks, some 
of which were randomly selected for sectioning, and 
some of the ultrathin sections were collected on grids for 
microscopy examination.
Count of immune-gold particles placed in the 
cytosol and in the nucleus, was carried out by electron 
microscopy at 8,000X magnification according to Lucocq 
et al. [64]. This magnification corresponds to the minimal 
magnification which allows identification of gold particles 
and cell compartments.
Each grid contained non-serial sections, and for each 
grid we observed an average of 10 cells. Several grids 
were observed in order to obtain a total number of 50 cells 
from each experimental group.
For quantifying immune-gold in ultrathin sections 
each observer started from the corner of a squared grid, 
to scan through equally spaced parallel sweeps across the 
specimens made up of a whole sectioned pellet. Random 
selection of the scanning erase on average those bias due 
to variations of cell density or intensity of gold labeling. 
For βIII-tubulin or nestin, in each cell the number of anti-
βIII-tubulin or anti-nestin immune-gold particles placed 
within cytoplasm and nucleus was counted, and it was 
expressed by the mean value of immune-gold particles for 
cell out of 50 cell counted.
RNA extraction for qRT-PCR
Total RNA was isolated from cultured cells using 
TRIzol Reagent (Invitrogen, Life Technologies) according 
to the manufacturer’s instructions. The concentration and 
purity of RNA samples were determined using Nanodrop 
2000 (Thermo Scientific, Life Technologies). Total RNA 
(1 μg) was reverse transcribed (RT) with SuperScript® 
VILO™ (Invitrogen, Life Technologies) with Oligo dT 
primers.
qReal-Time-PCR
Amplifcation and detection were performed on a 
CFX ConnectTM Real Time System (Bio-Rad, Hercules, 
CA, USA). PCR mix including 10 μl SYBR Green PCR 
Master (Applied Biosystems, Foster City, CA, USA), 0,5 
μM of each primer and 0,8 μl of RT reaction mix, was 
amplified as follows: 50°C for 1 minute, 95°C for 10 min 
followed by 40 cycles of 95°C for 30 s, 54°C for 1 m. 
The following primers have been designed using GenBank 
(http://www.ncbi.nlm.nih.gov/):
Nestin (NM_006617)5’-
TGGAGCAGGAGAAACAGG-3’;5’-
ATCTCTGCATCTACAGCAG-3’,TUBB3 
(NM_006086) 5’-AGTCATCAGTGATGAGCAT-
3’;5’-CAGGCCTGAAGAGATGTC-3’, 
NeuN (NM_001082575) 
5′-GCGGCTACACGTCTCCAACATC-3′;5′-
ATCGTCCCATTCAGCTTCTCCC-3′, B –Actin 
(NM_001101.3) 5’-GTGCGTGACATTAAGGAG-
3’;5’-GCCAGACAGCACTGTGT-3’, B-Globin 
(NM_000518.4) 5’-CTAAGGTGAAGGCTCATG-3’;5’-
GATAGGCAGCCTGCACT-3’. 
Positive controls (DNA), negative control (distilled 
water), and RT-negative controls (total RNA sample) were 
included in each run.
The relative quantification was calculated using 
comparative Ct method (also known as the ΔΔCT method) 
[65, 66], and beta-globin and beta-actin were selected as 
internal references. Ct values correspond to mean values 
of each PCR performed in triplicate. Gene expression was 
confirmed in two independent experiments using both 
beta-globin and beta-actin as internal references.
SDS-PAGE western blotting
Cells were homogenized at 4°C in ice-cold 
lysis buffer with phosphatase and protease inhibitor. 
One microliter of homogenates was used for protein 
determinations. Proteins (30 µg) were separated on 
sodium dodecyl sulphate polyacrylamide gels (7.5%) 
and transferred on Immuno-PVDF membranes (Bio-Rad, 
Milan, Italy) for 1 h. Filters were blocked overnight in 
Tween-20 Tris-buffered saline (TTBS) (100 mM Tris-
HCl, 0.9% NaCl, 1% Tween 20, pH 7.4) containing 5% 
non-fat dry milk. Blots were incubated overnight at 4°C 
with primary antibody mouse anti-GFAP (1:300, Sigma), 
mouse anti-β-III-tubulin (1:800, Millipore), rabbit anti-
nestin (1:2500, Millipore), rabbit anti-NeuN (1:2000, 
Millipore) or rabbit anti-pS6 (1:2000, Cell Signaling). 
For the normalization we have used β-actin. Blots were 
incubated with primary mouse monoclonal anti β-actin 
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antibody (1:50000, Sigma) for 1 h at room temperature. 
Filter was washed 3 times with TTBS buffer and then 
incubated for 1 h with secondary peroxidase-coupled 
antibodies (anti-mouse, 1:7000; Calbiochem, Milan, 
Italy). Immunostaining was revealed by enhanced 
chemiluminescence luminosity (GE Healthcare, Milan, 
Italy). Densitometric analysis was performed with ImageJ 
software. Data were obtained in duplicate or triplicate.
Chemotaxis assay
In parallel cultures from different laboratories 
2.5x105 cells were seeded on 35-mm Petri dishes in 
growth medium specific for each cell line. After 24 h, half 
of medium was replaced with fresh medium containing 
different treatments: vehicle (DMSO) or rapamycin at the 
final concentration of 10 nM, 100 nM or 1 µM; during 
longer treatments DMSO or rapamycin were added every 
24 h.
Chemotaxis experiments were performed with 
treated cells after 24 h and 72 h of treatment. Briefly, 
cells were trypsinized and re-suspended in chemotaxis 
medium (DMEM with 100 U/ml penicillin, 0.1 mg/ml 
streptomycin, 0.1% BSA and 25mM Hepes, pH 7.4) at a 
density of 2x105/ml. Cells were then plated on an 8µm 
pore polycarbonate membrane, in presence of chemotaxis 
medium with or without 10% FBS in the bottom well of a 
Boyden chamber.
After 3h of incubation at 37°C, membranes were 
washed in PBS, treated with ice-cold 10% trichloroacetic 
acid for 1 min and cells adhering to the upper side of the 
filter were scraped off, whereas cells on the lower side 
were stained with a solution containing 50% isopropanol, 
1% formic acid, and 0.5% (wt/vol) brilliant blue R 250. 
Stained cells were counted with a 20x objective.
Results are expressed as percentage of migrated 
cells in comparison with control (taken as 100%) and each 
count derives from the mean±SEM of 4-5 independent 
experiments. 
MTT assay
In the experimental conditions used to test cell 
migration viability was measured in rapamycin-treated 
cells with MTT assay a 24 h and 72 h as reported in 
Supplementary Figures 22 and 23. Briefly, 5 x 104 cells 
were seeded in 24-well plate and, after 24h, half of 
medium was replaced with fresh medium containing 
different treatments: vehicle (DMSO) or rapamycin at the 
final concentration of 10 nM, 100 nM or 1 µM; during 
longer treatments DMSO or rapamycin were added every 
24 h.
At the end of treatments, medium was changed with 
fresh medium containing 0.5 mg/ml of MTT and incubated 
at 37° C for 2 h; medium was then aspired and cells were 
treated with DMSO for 10 min. 
Samples absorbance was analyzed in a microplate 
reader at 570 and 630 nm to subtract background. Results 
are expressed as Viability Index, taking as 100% untreated 
cells in control condition.
Statistical analysis
Statistical analysis was performed using a statistical 
software (GraphPad Prism Software, version 5.0, apart 
from qRT-PCR in which the lab used the version 6.0).
Measures related to cell number and 
immunopositivity for stem-like and differentiation 
antigens were expressed as the mean percentage ± S.E.M. 
For cell morphometry, values were expressed as the mean 
number ± S.E.M. and the mean length ± S.E.M.
For ultrastructural morphometry related to the count 
of βIII-tubulin and nestin immune-gold particles, values 
were expressed as absolute numbers. Data are reported 
as the mean or the mean percentage ± S.E.M. Inferential 
statistics to compare groups was carried out by using One-
way analysis of variance, ANOVA, with Sheffè’s post-hoc 
analysis. Differences between groups were considered 
statistically significant when the null hypothesis (H0) was 
P ≤ 0.05.
For qRT-PCR experiments statistical analyses 
using one-way analysis of variance (ANOVA) followed 
by Bonferroni test using GraphPad Prism version 6.0 has 
been used to test differences in gene expression in basal 
and treated cells (P<0.05).
For western blot experiments, values of optical 
density were presented as the mean ± S.E.M. Analysis 
of variance (one-way ANOVA) was used to compare 
the experimental conditions and Bonferroni test was 
used to compare the mean values for all groups. The null 
hypothesis was rejected for P ≤ 0.05.
Data on cell migration were statistically analysed 
using One-Way ANOVA (N= 4 for chemotaxis 
experiments, N=3 for pFAK immune-fluorescence).
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